Through an HNSCC xenograft model of acquired resistance to bevacizumab, it was demonstrated that bevacizumab-resistant tumors maintained angiogenesis and prevented endothelial apoptosis, despite the sequestration of VEGF. This evidence concerns the gene VEGFA and head and neck squamous cell carcinoma.